Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 51-61

  Leung, Louis Y ^a   Lim, Heng Keang ^a,b   Abell, Madelyn W ^a   Zimmerman, James J ^a  

^a PFIZER INC   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Immunosuppressive activity; Metabolic disposition; Metabolites; Pharmacokinetics; Sirolimus

Indexed keywords

CARBON 14; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; RADIOACTIVITY; URINALYSIS; BLOOD; CLINICAL TRIAL; METABOLISM; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SIROLIMUS; TISSUE DISTRIBUTION;

EID: 33745498418     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000179838.33020.34     Document Type: Article

References (31)

1. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit. 1995;17:660-665.
2. Brattstrom C, Sawe J, Tyden G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit. 1997;19:397-406.
3. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 1998;66:1040-1046.
4. Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 1992;20:186-191.
5. Slatter M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
6. Leung LY, Lim HK, Hicks D, et al. Sirolimus (rapamycin): metabolite characterization in rat and human liver microsomal incubation, and in trough whole blood of renal transplant patients treated with sirolimus, cyclosporine and prednisone. ISSX Proc. 1996;10:366.
7. Streit F, Christians U, Schieel HM, et al. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab Dispos. 1996;24:1272-1278.
8. Wang CP, Chan KW, Schiksinis RA, et al. High performance liquid chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two rapamycin degradation products. J Liq Chromatogr. 1994;17:3383-3392.
9. Wang CP, Lim HK, Chan KW, et al. High performance liquid chromatographic isolation and spectroscopic characterization of three major metabolites from the plasma of rats receiving rapamycin (sirolimus) orally. J Liq Chromatogr. 1995;18:2559-2568.
10. Streit F, Christians U, Schiebel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in whole blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996;42:1417-1425.
11. Yatscoff R, LeGatt D, Keenan R, et al. Whole blood distribution of rapamycin. Transplantation. 1993;56:1202-1206.
12. Yatscoff RW, Wang P, Chan K, et al. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit. 1995;17:666-667.
13. Johnson EM, Zimmerman J, Duderstadt K, et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc. 1996;28:987.
14. Ferron GM, Mishina EV, Zimmerman JJ, et al. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther. 1997;61:416-428.
15. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 1997;37:405-415.
16. Zimmerman JJ, Ferron GM, Lim HK, et al. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol. 1999;39:1155-1161.
17. Cantone J, Chan K. Mass spectrometric characteristics of the immunosuppressive agent rapamycin. In: The 40th ASMS Conference on Mass Spectrometry and Allied Topics, 1992: 1881-1882.
18. SAS Institute, Inc. SAS User's Guide: Statistics. Cary NC: SAS Institute, Inc., 1989.
19. Kuhnt M, Bitsch F, Ponelle M, et al. Microbial conversion of rapamycin. Enzyme Microb Technol. 1997;21:405-412.
20. Brattstrom C, Sawe J, Jansson B, et al. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit. 2000;22:537-544.
21. Physicians' Desk Reference. 57th ed. Montvale. NJ: Medical Economics Company; 2004.
22. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43:1170-1180.
23. + ions generated by liquid secondary-ion mass spectrometry. Org Mass Spectrom. 1994;29:445-453.
24. Lim HK, Cinque T, Cantone J, et al. Quantitation of rapamycin: comparison between curtain gas and heated capillary API interfaces. In: Proceedings of the 44th ASMS Conference on Mass Spectrometry and Allied Topics, 1996:1324.
25. 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27:633-636.
26. Lampen A, Zhang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998;285:1104-1112.
27. Paine MF, Leung LY, Lim HK, et al. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J Pharmacol Exp Ther. 2002;99:174-186.
28. Cummins CL, Jacobsen W, Christians U, et al. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004;308:143-155.
29. Paine MF, Leung LY, Watkins PB. New insights into drug absorption. Studies with sirolimus. Ther Drug Monit. 2004;26:1-5.
30. Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits and rats. Drug Metab Dispos. 1998;26:83-84.
31. Hallensleben K, Raida M, Habermehl G. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J Am Soc Mass Spectrom. 2000;11:516-525.